Genocea Biosciences, Inc. - Common Stock (GNCA) Covered Calls

You can sell covered calls on Genocea Biosciences, Inc. - Common Stock to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for GNCA (prices last updated Fri 4:16 PM ET):

Genocea Biosciences, Inc. - Common Stock (GNCA) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
3.63 -0.03 3.60 3.67 153K -2.7 0.1B
Covered Calls For Genocea Biosciences, Inc. - Common Stock (GNCA)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Aug 16 2.5 0.90 2.77 -9.7% -122.1%
Nov 15 2.5 0.15 3.52 -29.0% -88.2%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform AnTigen Lead Acquisition System to design immunotherapies and vaccines that act through T cell immune responses. Its lead product candidate is GEN-003, an investigational immunotherapy that is in Phase III trial for the treatment of genital herpes infections. The company is also develops GEN-009, which is in pre-clinical stage to treat neoantigen cancer; GEN-010 that is in pre-clinical stage for the treatment of patients in second generation neoantigen cancer; GEN-007, which is in research stage to Epstein-Barr virus; and GEN-006 that is in research stage for the treatment of immune-oncology-tumor-associated antigen cancer. It license agreement with University of California and Harvard University; and collaboration agreement with Novavax, Inc. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.